Literature DB >> 36471

Hyperactivity response to apomorphine and amphetamine in the mouse: the importance of the nucleus accumbens and caudate-putamen.

B Costall, R J Naylor, V Nohria.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 36471     DOI: 10.1111/j.2042-7158.1979.tb13494.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


× No keyword cloud information.
  6 in total

1.  Effects of amphetamine and apomorphine on locomotor activity after kainic acid lesion of the nucleus accumbens septi in the rat.

Authors:  E Kafetzopoulos
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  On the importance of mesolimbic mechanisms for the control of apomorphine induced climbing behaviour in the mouse [proceedings].

Authors:  B Costall; R J Naylor; V Nohria
Journal:  Br J Pharmacol       Date:  1980-01       Impact factor: 8.739

3.  The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice.

Authors:  J M Wierońska; M Kusek; K Tokarski; J Wabno; W Froestl; A Pilc
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

4.  Rat climbing behavior elicited by stimulation of cerebral dopamine receptors.

Authors:  P Protais; J J Bonnet; J Costentin; J C Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-02       Impact factor: 3.000

5.  Dopamine agonist action in mesolimbic, cortical and extrapyramidal areas to modify spontaneous climbing behaviour of the mouse.

Authors:  B Costall; J F Eniojukan; R J Naylor
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

6.  Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia.

Authors:  Joanna M Wierońska; Katarzyna Stachowicz; Francine Acher; Tomasz Lech; Andrzej Pilc
Journal:  Psychopharmacology (Berl)       Date:  2011-09-28       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.